ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2 BreastПодробнее

Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBCПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-posi...Подробнее

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in...Подробнее

PerELISA: de-escalated therapy for HR+/HER2+ BC with Ki67 response following 2-week letrozoleПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBCПодробнее

APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

INNOVATION: chemotherapy with trastuzumab and pertuzumab in HER2+ gastric cancerПодробнее

Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast CancerПодробнее

Treatment de-escalation and escalation strategies in HER2-positive breast cancerПодробнее

ABP 980, a trastuzumab biosimilar in combination with pertuzumabПодробнее

HER2-E pCR with anti-HER2-based neoadjuvant therapiesПодробнее

WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancerПодробнее

PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BCПодробнее